221 related articles for article (PubMed ID: 16105559)
41. Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.
Kronvall G; Karlsson I; Walder M; Sörberg M; Nilsson LE
J Antimicrob Chemother; 2006 Mar; 57(3):498-505. PubMed ID: 16410264
[TBL] [Abstract][Full Text] [Related]
42. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
[TBL] [Abstract][Full Text] [Related]
43. Tigecycline: a critical analysis.
Stein GE; Craig WA
Clin Infect Dis; 2006 Aug; 43(4):518-24. PubMed ID: 16838243
[TBL] [Abstract][Full Text] [Related]
44. Differences in determining in vitro tigecycline susceptibility according to the agar medium used.
Leal AL; Buitrago G; Ovalle MV; Cortés JA; Alvarez CA; Larrota J;
J Chemother; 2010 Apr; 22(2):137-8. PubMed ID: 20435576
[No Abstract] [Full Text] [Related]
45. Tigecycline pharmacokinetic/pharmacodynamic update.
MacGowan AP
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i11-6. PubMed ID: 18684702
[TBL] [Abstract][Full Text] [Related]
46. Tigecycline: a single antibiotic for polymicrobial infections.
Pankey GA; Steele RW
Pediatr Infect Dis J; 2007 Jan; 26(1):77-8. PubMed ID: 17195711
[No Abstract] [Full Text] [Related]
47. Comparative in vitro antimicrobial activity of tigecycline against clinical isolates of vancomycin-resistant enterococcus.
Yemisen M; Demirel A; Mete B; Kaygusuz A; Mert A; Tabak F; Ozturk R
Indian J Med Microbiol; 2009; 27(4):373-4. PubMed ID: 19736414
[No Abstract] [Full Text] [Related]
48. In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.
Cercenado E; Cercenado S; Gómez JA; Bouza E
J Antimicrob Chemother; 2003 Jul; 52(1):138-9. PubMed ID: 12805264
[No Abstract] [Full Text] [Related]
49. Tigecycline: what is it, and where should it be used?
Livermore DM
J Antimicrob Chemother; 2005 Oct; 56(4):611-4. PubMed ID: 16120626
[TBL] [Abstract][Full Text] [Related]
50. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit.
Ratnam I; Franklin C; Spelman DW
Pathology; 2007 Dec; 39(6):586-8. PubMed ID: 18027263
[TBL] [Abstract][Full Text] [Related]
51. In vitro activity of tigecycline against gram-positive cocci: a multicentre study in Greece.
Malli E; Spiliopoulou I; Kolonitsiou F; Neocleous Ch; Klapsa D; Pantelidi K; Panopoulou M; Grapsa S; Alepopoulou E; Neonakis I; Alexiou-Daniel S; Bakola D; Koutsia-Carouzou C; Malamou-Lada H; Zerva L; Vlahaki E; Kartali-Ktenidou S; Anastassiou E; Petinaki E
J Antimicrob Chemother; 2008 Nov; 62(5):1158-60. PubMed ID: 18753190
[No Abstract] [Full Text] [Related]
52. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens.
Vouillamoz J; Moreillon P; Giddey M; Entenza JM
J Antimicrob Chemother; 2008 Feb; 61(2):371-4. PubMed ID: 18033780
[TBL] [Abstract][Full Text] [Related]
53. EUCAST technical note on tigecycline.
European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee
Clin Microbiol Infect; 2006 Nov; 12(11):1147-9. PubMed ID: 17063597
[No Abstract] [Full Text] [Related]
54. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
[TBL] [Abstract][Full Text] [Related]
55. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Boucher HW; Wennersten CB; Eliopoulos GM
Antimicrob Agents Chemother; 2000 Aug; 44(8):2225-9. PubMed ID: 10898710
[TBL] [Abstract][Full Text] [Related]
56. Tigecycline.
Frampton JE; Curran MP
Drugs; 2005; 65(18):2623-35; discussion 2636-7. PubMed ID: 16392879
[TBL] [Abstract][Full Text] [Related]
57. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
Timurkaynak F; Arslan H; Azap OK; Senger SS; Başaran O; Karaman SO; Haberal M
Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
[TBL] [Abstract][Full Text] [Related]
58. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains.
Katsandri A; Avlamis A; Pantazatou A; Petrikkos GL; Legakis NJ; Papaparaskevas J;
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):231-6. PubMed ID: 16626904
[TBL] [Abstract][Full Text] [Related]
59. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth.
Petersen PJ; Jones CH; Bradford PA
Diagn Microbiol Infect Dis; 2007 Nov; 59(3):347-9. PubMed ID: 17662552
[TBL] [Abstract][Full Text] [Related]
60. [Sensitivity of bacteria to therapeutic drugs (Zurich 1996)].
Wüst J; Zbinden R; Kayser FH
Praxis (Bern 1994); 1998 Mar; 87(12):403-12. PubMed ID: 9564237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
